港股異動 | 深圳控股(00604.HK)升超6% 3月銷售額環比大增10倍
格隆匯4月27日丨深圳控股(00604.HK)低位反彈,現升6.55%,報2.44港元,暫成交9249萬港元,最新總市值215.5億港元。深圳控股24日宣佈,2020年3月份集團合同銷售額約為人民幣13.89億元,較上個月上漲約1029.3%。1-3月份,集團總合同銷售額約25.71億元,較去年同期上漲77.4%。管理層透露3月份有85%售樓處已重新開放,預計5月份銷情將有所恢復。花旗曾預期隨着公司未來更加積極的併購土地,加深與深圳政府在養老、醫療及PPP項目等合作,依靠國企背景大有發展機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.